Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Neuroimmune Pharmacol ; 15(2): 326-339, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-31927682

RESUMO

Both brain-derived neurotrophic factor (BDNF) and microglia activation are involved in the pathogenesis of ischemic stroke. Herein, we attempt to ascertain whether Calycosin, an isoflavonoid, protects against ischemic stroke by modulating the endogenous production of BDNF and/or the microglia activation. This study was a prospective, randomized, blinded and placebo-controlled preclinical experiment. Sprague-Dawley adult rats, subjected to transient focal cerebral ischemia by middle cerebral artery occlusion (MCAO), were treated randomly with 0 (corn oil and/or saline as placebo), 30 mg/kg of Calycosin and/or 1 mg/kg of a tropomyosin-related kinase B (TrkB) receptor antagonist (ANA12) at 1 h after reperfusion and once daily for a total of 7 consecutive days. BDNF and its functional receptor, full-length TrkB (TrkB-FL) levels, the percentage of hypertrophic microglia, tumor necrosis factor-α (TNF-α)-containing microglia, and degenerative and apoptotic neurons in ischemic brain regions were determined 7 days after cerebral ischemia. A battery of functional sensorimotor test was performed over 7 days. Post-stroke Calycosin therapy increased the cerebral expression of BDNF/TrkB, ameliorated the neurological injury and switched the microglia from the activated amoeboid state to the resting ramified state in ischemic stroke rats. However, the beneficial effects of BDNF/ TrkB-mediated Calycosin could be reversed by ANA12. Our data indicate that BDNF/TrkB-mediated Calycosin ameliorates rat ischemic stroke injury by switching the microglia from the activated amoeboid state to the resting ramified state. Graphical abstract.


Assuntos
Isquemia Encefálica/tratamento farmacológico , Fator Neurotrófico Derivado do Encéfalo/biossíntese , Isoflavonas/uso terapêutico , Microglia/efeitos dos fármacos , Receptor trkB/biossíntese , Acidente Vascular Cerebral/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Encéfalo/patologia , Isquemia Encefálica/metabolismo , Isquemia Encefálica/patologia , Medicamentos de Ervas Chinesas/farmacologia , Medicamentos de Ervas Chinesas/uso terapêutico , Isoflavonas/farmacologia , Masculino , Microglia/metabolismo , Microglia/patologia , Ratos , Ratos Sprague-Dawley , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/fisiologia , Acidente Vascular Cerebral/metabolismo , Acidente Vascular Cerebral/patologia , Fator de Necrose Tumoral alfa/metabolismo
2.
Cell Transplant ; 26(11): 1798-1810, 2017 11.
Artigo em Inglês | MEDLINE | ID: mdl-29338384

RESUMO

Microglia are the first source of a neuroinflammatory cascade, which seems to be involved in every phase of stroke-related neuronal damage. Two weeks after transient middle cerebral artery occlusion (MCAO), vehicle-treated rats displayed higher numbers of total ionized calcium-binding adaptor molecule 1 (Iba-1)-positive cells, greater cell body areas of Iba-1-positive cells, and higher numbers of hypertrophic Iba-1-positive cells (with a cell body area over 80 µm2) in the ipsilateral ischemic brain regions including the frontal cortex, striatum, and parietal cortex. In addition, MCAO decreased the number of migrating neuroblasts (or DCX- and 5-ethynyl-2'-deoxyuridine-positive cells) in the cortex, subventricular zone, and hippocampus of the ischemic brain, followed by neurological injury (including brain infarct and neurological deficits). Intravenous administration of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs; 1 × 106 or 4 × 106) at 24 h after MCAO reduced neurological injury, decreased the number of hypertrophic microglia/macrophages, and increased the number of newborn neurons in rat brains. Thus, the accumulation of hypertrophic microglia/macrophages seems to be detrimental to neurogenesis after stroke. Treatment with hUC-MSCs preserved adult newborn neurons and reduced functional impairment after transient cerebral ischemia by reducing the number of hypertrophic microglia/macrophages.


Assuntos
Isquemia Encefálica/terapia , Terapia Baseada em Transplante de Células e Tecidos/métodos , Células-Tronco Mesenquimais/citologia , Neurônios/citologia , Cordão Umbilical/citologia , Análise de Variância , Animais , Proliferação de Células/fisiologia , Modelos Animais de Doenças , Proteína Duplacortina , Humanos , Imuno-Histoquímica , Macrófagos/citologia , Macrófagos/fisiologia , Masculino , Células-Tronco Mesenquimais/fisiologia , Microglia/citologia , Microglia/fisiologia , Neurônios/fisiologia , Ratos , Ratos Sprague-Dawley
3.
Mol Carcinog ; 55(2): 182-92, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25620490

RESUMO

Cr(VI) causes severe kidney damage. The patient's renal function could gradually recover by spontaneous kidney regeneration. The molecular effect of Cr(VI) on recovery of kidney cells, however, has not been clearly elucidated. Here we show that Cr(VI) induces expression of mesenchymal and stem cell markers, cell markers, such as paxillin, vimentin, α-SMA, nanog, and CD133 of HK-2 cells. Moreover, Cr(VI) activates epithelial-to-mesenchymal transition (EMT). By revealing that levels of dihydrodiol dehydrogenase were promptly reduced following Cr(VI) challenge, our data suggested that DDH could be involved in a Cr(VI)-related oxidation to generate massive reactive oxygen species and H2 O2 , and to create intracellular hypoxia, which then increased levels of SUMO-1 activating enzyme subunit 2, and sumoylation of eukaryotic elongation factor-2, to mediate the subsequent molecular and cellular responses, e.g., expression of mesenchymal and stem cell markers. Pretreatment with vitamin C reduced Cr(VI)-related cellular effects. However, no evident effect was observed when vitamin C was added following Cr(VI) challenge.


Assuntos
Biomarcadores/metabolismo , Cromo/efeitos adversos , Células Epiteliais/efeitos dos fármacos , Rim/citologia , Células-Tronco Mesenquimais/metabolismo , Antígeno AC133 , Actinas/metabolismo , Antígenos CD/metabolismo , Ácido Ascórbico/farmacologia , Linhagem Celular , Proliferação de Células/efeitos dos fármacos , Células Epiteliais/citologia , Células Epiteliais/metabolismo , Transição Epitelial-Mesenquimal/efeitos dos fármacos , Regulação da Expressão Gênica/efeitos dos fármacos , Glicoproteínas/metabolismo , Proteínas de Homeodomínio/metabolismo , Humanos , Proteína Homeobox Nanog , Oxirredutases/metabolismo , Peptídeos/metabolismo , Vimentina/metabolismo
4.
Opt Express ; 20(7): 7445-53, 2012 Mar 26.
Artigo em Inglês | MEDLINE | ID: mdl-22453424

RESUMO

The purpose of this study is to reduce the glass substrate reflectivity over a wide spectral range (400-1200 nm) without having high reflectivity in the near-infrared region. After making porous SiO2/MgF2 double-layer antireflection (DLAR) thin film structure, the superstrate-type silicon-based tandem cells are added. In comparison to having only silicon-based tandem solar cells, the short-circuit current density has improved by 6.82% when porous SiO2/MgF2 DLAR thin film is applied to silicon-based tandem solar cells. This study has demonstrated that porous SiO2/MgF2 DLAR thin film structure provides antireflection properties over a broad spectral range (400-1200 nm) without having high reflectivity at near-infrared wavelengths.


Assuntos
Fluoretos/química , Lentes , Compostos de Magnésio/química , Dióxido de Silício/química , Silício/química , Desenho de Equipamento , Análise de Falha de Equipamento , Luz , Porosidade , Espalhamento de Radiação
5.
J Biol Chem ; 278(46): 46007-13, 2003 Nov 14.
Artigo em Inglês | MEDLINE | ID: mdl-12952958

RESUMO

The flavivirus envelope protein is the dominant antigen in eliciting neutralizing antibodies and plays an important role in inducing immunologic responses in the infected host. We have determined the solution structure of the major antigenic domain (domain III) of the Japanese encephalitis virus (JEV) envelope protein. The JEV domain III forms a beta-barrel type structure composed of six antiparallel beta-strands resembling the immunoglobulin constant domain. We have also identified epitopes of the JEV domain III to its neutralizing antibody by chemical shift perturbation measurements. Site-directed mutagenesis experiments are performed to confirm the NMR results. Our study provides a structural basis for understanding the mechanism of immunologic protection and for rational design of vaccines effective against flaviviruses.


Assuntos
Vírus da Encefalite Japonesa (Espécie)/metabolismo , Flavivirus/química , Produtos do Gene env/química , Sequência de Aminoácidos , Anticorpos/química , Anticorpos Monoclonais , Antígenos/química , Epitopos , Flavivirus/metabolismo , Produtos do Gene env/metabolismo , Espectroscopia de Ressonância Magnética , Modelos Moleculares , Dados de Sequência Molecular , Mutagênese Sítio-Dirigida , Conformação Proteica , Estrutura Secundária de Proteína , Estrutura Terciária de Proteína , Homologia de Sequência de Aminoácidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA